LINC01210: A Potential Drug Target and Biomarker (G100507274)

Target Name: LINC01210

NCBI ID: G100507274

LINC01210

Other Name(s): long intergenic non-protein coding RNA 1210 | Long intergenic non-protein coding RNA 1210

LINC01210: A Potential Drug Target and Biomarker

LINC01210 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell-cycle and has been shown to play a role in various diseases, including cancer. LINC01210 has also been shown to have potential as a therapeutic target in human diseases, including cancer. In this article, we will explore the potential drug target and biomarker properties of LINC01210 and its potential therapeutic applications.

Potential Drug Target

LINC01210 is a key regulator of the cell-cycle and has been shown to play a role in various diseases, including cancer. It has been shown to promote the G1 phase of the cell-cycle, which is the stage of growth and development, and can also inhibit the G2 phase of the cell-cycle, which is the stage of preparation for cell division. LINC01210 has also been shown to play a role in the regulation of cell apoptosis, which is the process by which cells die and are removed from the body.

Research has shown that LINC01210 can be a potential drug target for cancer, as it has been shown to promote the growth and survival of cancer cells. LINC01210 has also been shown to interact with several transcription factors, including PDGF, TGF-β1, and NF-kappa-B. These transcription factors are important for the regulation of cell-cycle progression and have been implicated in the development and progression of cancer.

Potential Biomarker

LINC01210 has also been shown to have potential as a biomarker for cancer. LINC01210 has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that LINC01210 may be a useful biomarker for the diagnosis and prognosis of these cancers.

In addition, LINC01210 has also been shown to be regulated by several factors, including PSA, progesterone, and estrogen. These factors have been shown to play a role in the development and progression of cancer. By studying the regulation of LINC01210 by these factors, researchers may be able to gain insights into the underlying mechanisms of cancer development and progression.

Therapeutic Applications

The potential therapeutic applications of LINC01210 are vast. LINC01210 has been shown to promote the growth and survival of cancer cells, making it an attractive target for cancer therapies. LINC01210 has also been shown to interact with several transcription factors, making it a potential target for drugs that target these transcription factors.

One potential therapeutic approach for LINC01210 is to use small molecules or antibodies to inhibit its activity. This could be done by targeting the specific transcription factors that LINC01210 interacts with, such as PDGF, TGF-β1, and NF-kappa-B. By inhibiting LINC01210's activity, researchers may be able to reduce the growth and survival of cancer cells.

Another potential therapeutic approach for LINC01210 is to use drugs that target its activity in the cell-cycle. LINC01210 has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells die and are removed from the body. By targeting LINC01210's activity in this process, researchers may be able to inhibit its role in the development and progression of cancer.

Conclusion

In conclusion, LINC01210 is a non-coding RNA molecule that has

Protein Name: Long Intergenic Non-protein Coding RNA 1210

The "LINC01210 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01210 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets